My take is the Amarex issue is hindering the HIV and Covid data so badly that the data is going to have to be rebuilt from the mess they have given Cydy.

Nothing in this PR states what's happening with NASH, TnBC, and other indications coming with the new CRO managing that data so I believe we will see a new focus.

A holdd on those two indications isn't a huge surprise with what's happened lately.

Let's be positive and see what the strategic direction that the board is driving and I believe things will fall in place when the timing is right.

We all know the FDA has been a bit less than fair to this company but such is life...